Extended Data Fig. 8: Therapeutic actionability of variants.
From: Pan-cancer whole-genome comparison of primary and metastatic solid tumours
a) Cancer type-specific fraction of primary (top) and metastatic (bottom) patients with reported therapeutically actionable variants. For each patient the variant with the greatest level of evidence was considered. Bars are coloured according to the variant actionability tiers. Fold change (i.e., metastatic divided by primary fraction) labels are displayed in cancer types with a significant proportional increase (two-sided Fisher’s exact test adjusted p-value < 0.05). Purple edgelines highlight significant increase in metastatic A-on label fraction patients. b) Primary (left) and metastatic (right) alteration frequency of actionable variants with a high discrepancy (>5% frequency difference) from cancer types with a global significant increase of actionable variants in metastatic tumor patients from panel a). “*”, a two-sided Fisher’s exact test adjusted p-value < 0.05. Text boxes include the associated treatments for alterations with a significant mutation frequency increase in metastatic tumor patients.
